TumourGraft
TumourGraft: Cancer diagnostic using PDX models. Global launch in UK, Israel, Singapore, USA. Shifted to pharmaceutical partnerships from patient services, expanding revenue and ensuring technology sustainability.
PredictRx
PredictRx: In-vitro diagnostic for cancer drug sensitivity. Led global commercialisation for clinical use and research. Established Indian reference lab, sales channels in UK, South Africa, Scandinavia. Facilitated successful exit strategy for Imagen Therapeutics.
Caris molecular intelligence
Caris Molecular Intelligence: Molecular profiling for cancer therapy biomarkers. Introduced first UK technology, formed global Expert Panel. Earned NICE endorsement, PMI reimbursement in private sector. Top international distributor for Caris, achieving substantial annual growth.
TEMPUS oncology test suite
Our collection of genomic tests uncover unique insights that empower you to customise treatment for individual patients, throughout their cancer journey.
APIS breast cancer subtyping kit
Receptor tyrosine-protein kinase erbB-2 (HER2), oestrogen receptor (ER), progesterone receptor (PR), and marker of proliferation Ki67 expression plays a key role in breast cancer intrinsic subtype evaluation and guides treatment decisions. The APIS Breast Cancer Subtyping Kit is an RNA-based diagnostic workflow for detecting mRNA expression of standard biomarkers (HER2, ER, PR, Ki67) and a novel proliferative signature from pre-operative core needle biopsy (CNB) or resected formalin-fixed paraffin-embedded (FFPE) breast tumour tissue. The test serves as an alternative method to current standard of care – immunohistochemistry (IHC).